THE GLOBAL MARKET.
In Europe and the USA, ID-NEST Medical solutions are positioned on a total market estimated at
1.2-1.4 billion €
COMPRESSIONS AND SEVERE VENOUS THROMBOSES OF THE LOWER LIMBS.
The treatment of these pathologies is not very effective using current techniques.
This mass market, with no lasting medical solution, is growing at the same rate as the population.
The market for severe venous pathologies of the lower limbs is estimated at
1.2 billion €
(Europe and USA, in 2017.).
ID Venous System may be especially effective in treating four specific indications, as a complement to the techniques currently used :
- Acute episode – May-Thurner type thrombotic patients.
- Acute episode – Patients in proximal deep vein thrombosis with obstructive risk.
- Chronic pathology – Patients with severe obstructive after effects as the result of a deep vein thrombosis.
- Chronic pathology – Symptomatic, non-thrombosed patients with May-Thurner type compression.
- Total.
ID VENOUS SYSTEM PER PATHOLOGY, IN MILLION €.
MARKET SHARE AND NUMBER OF STENTS SOLD.
2022
3,000 stents sold.
0.3%
2023
6,800 stents sold.
0.7%
2024
13,000 stents sold.
1.4%
2025
26,100 stents sold.
2.7%
2026
43,700 stents sold.
4.6%
2027
70,300 stents sold.
7.3%
2028
91,500 stents sold.
9.6%
2029
123,100 stents sold.
12.8%
2030
153,800 stents sold.
16%
END USER TURNOVER.
Total 31 M€ in 2025
- USA 7M€
- Europe 24M€
Total 110 M€ in 2027
- USA 72M€
- Europe 38M€
Total 184 M€ in 2029
- USA 145M€
- Europe 39M€
ANEURYSMS AND DISSECTIONS OF THE
AORTIC ARCH.
The treatment of these pathologies by 100% endoscopic approach represents a budding niche market with high Added Value in which ID Arterial System will be the first effective solution.
The market for aneurysms and dissections of the Aortic Arch treated by endoscopy is estimated at
220 million €
in 2027.
- Total market share for aneurysms and dissections of the Aortic Arch treated by endoscopy.
- Share acquired by ID Arterial System by 2025.
Its growth will depend especially on the adequacy of Medical Devices for the anatomical constraints of such operations. Owing to its modular design, ID Arterial System is especially well placed to take a significant share of this market, approximately 40% by 2025.
The solutions currently available on the market are unsatisfactory, for their mortality/morbidity rate is deemed to high (18%). Therefore, the US FDA does not currently authorise the sale of branched arterial endoprostheses intended specifically for the treatment of Aortic Arch pathologies. Thanks to its ease of implementation and its higher compliance, ID Arterial System is the first branched arterial endoprosthesis that could be released in the United States.
Market data on the four biggest European markets :
TOTAL TURNOVER ARTERIAL IN MILLION €.
NUMBER OF DEVICES SOLD.
- 40
- 220
- 1570
- 2470
- 3280
- 3870
- 4560
ID-NEST MARKET SHARE.
PROVISIONAL PLANNING.
